Showing results (121-130 of 193) with videos related to
Sort By:
Pageof 20
European Journal of Gastroenterology & Hepatology|June 6, 2014
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infectionAdrian M Di Bisceglie, Mark Sulkowski, Ed Gane, et al.Blood|April 30, 2005
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis CDavid Butera, Svetlana Marukian, Amy E Iwamaye, et al.Journal of Gastroenterology and Hepatology|March 8, 2023
Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of diseaseDavid E Kleiner, Mauricio Lisker-Melman, Abdus S Wahed, et al.Alimentary Pharmacology & Therapeutics|September 20, 2024
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patientsAnna Fettiplace, John Marcinak, Michael Merz, et al.Hepatology (Baltimore, Md.)|July 27, 2007
Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United StatesMarion G Peters, Adrian M Di Bisceglie, Kris V Kowdley, et al.Virology Journal|April 26, 2005
Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysisStephen J Polyak, Daniel G Sullivan, Michael A Austin, et al.Hepatology (Baltimore, Md.)|August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.Drug Safety|December 4, 2025
Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert ConsensusAnna Fettiplace, Arie Regev, Alexandre Kiazand, et al.The American Journal of Gastroenterology|June 13, 2012
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis CChihiro Morishima, Mitchell L Shiffman, Jules L Dienstag, et al.The American Journal of Gastroenterology|February 2, 2023
Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment TrialJordan J Feld, Abdus S Wahed, Michael Fried, et al.Pageof 20